Cadence Pharmaceuticals, (FRA:QEW) Debt-to-Equity : 0.84 (As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Debt-to-Equity?

Cadence Pharmaceuticals,'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2013 was €7.87 Mil. Cadence Pharmaceuticals,'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2013 was €13.53 Mil. Cadence Pharmaceuticals,'s Total Stockholders Equity for the quarter that ended in Dec. 2013 was €25.46 Mil. Cadence Pharmaceuticals,'s debt to equity for the quarter that ended in Dec. 2013 was 0.84.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cadence Pharmaceuticals,'s Debt-to-Equity or its related term are showing as below:

FRA:QEW's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Cadence Pharmaceuticals, Debt-to-Equity Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Debt-to-Equity Chart

Cadence Pharmaceuticals, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Debt-to-Equity

Get a 7-Day Free Trial

0.09

0.23

0.24

0.60

0.84

Cadence Pharmaceuticals, Quarterly Data
	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13
Debt-to-Equity	Get a 7-Day Free Trial															0.60	0.60	0.75	0.85	0.84

Competitive Comparison of Cadence Pharmaceuticals,'s Debt-to-Equity

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cadence Pharmaceuticals,'s Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s Debt-to-Equity falls into.

Cadence Pharmaceuticals, Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cadence Pharmaceuticals,'s Debt to Equity Ratio for the fiscal year that ended in Dec. 2013 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.867	+	13.533)	/	25.461
	=	0.84

Cadence Pharmaceuticals,'s Debt to Equity Ratio for the quarter that ended in Dec. 2013 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.867	+	13.533)	/	25.461
	=	0.84

Cadence Pharmaceuticals, (FRA:QEW) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cadence Pharmaceuticals, Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadence Pharmaceuticals, (FRA:QEW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cadencepharm.com

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines